Argonaute RNA Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Argonaute RNA Ltd. - overview
Established
2015
Location
Bristol, -, UK
Primary Industry
Biotechnology
About
Based in Bristol, UK, and founded in 2015 by Anthony Parker, and Richard Tompkins, Argonaute RNA Ltd. operates as a biotechnology company that creates small interfering RNA drugs that effectively prevent protein production. In July 2024, Argonaute RNA Ltd. raised GBP 1.
75 million in venture funding led by new investor Development Bank of Wales, with participation from another new investor Empirical Ventures. Returning investors The Fink Family Office and Bristol Private Equity Club also participated in the round. As of March 2023, Mike Khan is the Chief Executive Officer (CEO). Argonaute RNA Ltd.
is a therapeutic medicine developer who uses the body's natural cell mechanisms to silence specific genes and fight illness. The company's platform employs a method of maintaining small interfering RNA, thereby avoiding a number of issues that have previously proven significant barriers to developing small interfering RNA drugs for human use, allowing healthcare professionals to access effective therapeutics that prevent the production of a specific protein. Furthermore, the firm demonstrates how their specialized modification of small interfering RNA (siRNA) allows for safe and effective gene silencing. The company plans to use the July 2024 funding to advance the accessibility of therapy for clinics and patients.
Current Investors
Fink Family Foundation, Bristol Private Equity Club, CatSci Ltd.
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Molecular Science, Genetics & Gene Therapy
Website
www.argonauterna.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.